1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood and bone marrow cancers

Imetelstat for treating intermediate-2 or high-risk relapsed or refractory myelofibrosis after a JAK inhibitor TS ID 8376

Awaiting development [GID-TA11608] Expected publication date: TBC

  • Project information
  • Project documents

10242-Imetelstat-for-Myelofibrosis-V1.0-JUN2024-NON-CONF.pdf (nihr.ac.uk)